SU11248: An oral multitargeted tyrosine kinase inhibitor with promising activity in metastatic renal cell carcinoma

被引：0
|
作者：
Sternberg, CN [1 ]
机构：
[1] Can Camillo & Forlanini Hosp, Dept Med Oncol, I-00152 Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：17 / 17
页数：1
相关论文
共 50 条
  • [21] Response to a Novel Multitargeted Tyrosine Kinase Inhibitor Pazopanib in Metastatic Merkel Cell Carcinoma
    Davids, Matthew
    Charlton, Amanda
    Ng, Swee-Siang
    Chong, Mei-Ling
    Laubscher, Kevin
    Dar, Mohammed
    Hodge, Jeffrey
    Soong, Richie
    Goh, Boon Cher
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) : E97 - E100
  • [22] Phase II study of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (MRCC)
    Rini, Brian I.
    George, Daniel J.
    Michaelson, M. Dror
    Rosenberg, Jonathan E.
    Bukowski, Ronald M.
    Sosman, Jeffrey A.
    Stadler, Walter M.
    Margolin, Kim
    Hutson, Thomas E.
    Baum, Charles M.
    ANNALS OF ONCOLOGY, 2006, 17 : 144 - 144
  • [23] Sunitinib malate (SU11248) shows antitumour activity in patients with metastatic renal cell carcinoma: updated results from phase II trials
    Motzer, R.
    Rini, B.
    Michaelson, M.
    Redman, B.
    Hudes, G.
    Wilding, I.
    Bukowski, R.
    George, D.
    Kim, S.
    Baum, C.
    EJC SUPPLEMENTS, 2005, 3 (02): : 227 - 227
  • [24] Use of SU11248 to inhibit proangiogenic growth factors in renal-cell carcinoma patients
    Kate Matthews
    Nature Clinical Practice Oncology, 2006, 3 (3): : 119 - 119
  • [25] Cabozantinib: A Multitargeted Oral Tyrosine Kinase Inhibitor
    Markowitz, Jordan N.
    Fancher, Karen M.
    PHARMACOTHERAPY, 2018, 38 (03): : 357 - 369
  • [26] Phase II study of SU 11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC).
    Miller, KD
    Burstein, HJ
    Elias, AD
    Rugo, HS
    Cobleigh, MA
    Pegram, MD
    Eisenberg, PD
    Collier, M
    Adams, BJ
    Baum, CM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 19S - 19S
  • [27] Panniculitis in a patient with metastatic renal cell carcinoma on a tyrosine kinase inhibitor
    Nafissi, Nellie N.
    Karlin, Nina
    Pittelkow, Mark R.
    Dicaudo, David J.
    Mangold, Aaron R.
    ANTI-CANCER DRUGS, 2021, 32 (04) : 474 - 475
  • [28] An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases
    Kim, Dong Wook
    Jo, Young Suk
    Jung, Hye Sook
    Chung, Hyo Kyun
    Song, Jung Hun
    Park, Ki Cheol
    Park, Su Hyeon
    Hwang, Jung Hwan
    Rha, So Young
    Kweon, Gi Ryang
    Lee, Su-Jae
    Jo, Ki-Won
    Shong, Minho
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (10): : 4070 - 4076
  • [29] Consolidative renal cell carcinoma metastatectomy for partial response after multitargeted tyrosine kinase inhibitor therapy
    Neill, Mischel G.
    Wei, Alice C.
    Jewett, Michael A. S.
    UROLOGY, 2007, 70 (01) : 178.e9 - 178.e11
  • [30] Synthesis and Metabolic Stability of 11C-Labelled SU11248 Derivative as Inhibitor of Tyrosine Kinases
    Kniess, T.
    Bergmann, R.
    Steinbach, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S310 - S311
12345